Latest reviews had concluded the role of EZH2 in the poor prognosis of a variety of cancers and the underlying potentiality of EZH2 inhibitors among cancer treatment (Yamagishi and Uchimaru 2017; Kim and Roberts 2016). The gene discussed is EZH2; the disease is cancer.